Organon (OGN) Insider Helene Gayle Buys $240K of Stock

On June 12, 2026, Helene Gayle made a significant purchase of Organon & Co. shares. She acquired 17,857 shares at a price of $13.44 each, totaling approximately $239,998.08. This transaction was not pre-planned, indicating a deliberate decision to invest.

Insider Buying and Selling at Organon & Co.

Several insiders joined Helene Gayle in purchasing shares of Organon & Co. on the same date. Shalini Sharp, Philip Ozuah, Ramona Sequeira, Deborah Leone, Cynthia Patton, and Rochelle Lazarus each bought 17,857 shares at $13.44 per share. None of these transactions were pre-planned, suggesting a collective confidence in the company's prospects.

Other Institutional Activity in Organon & Co.

In recent institutional activity, BlackRock, Inc. increased its holdings by 751,009 shares, bringing its total to 31,717,028 shares valued at about $189.98 million. Vanguard Portfolio Management LLC entered a new position with 21,846,036 shares worth approximately $130.86 million. Similarly, Vanguard Capital Management LLC initiated a new stake with 11,737,018 shares, valued at around $70.30 million. State Street Corp also boosted its holdings by 359,013 shares to a total of 9,956,774 shares, valued at $59.64 million. However, LSV Asset Management reduced its position by 212,699 shares, leaving it with 7,259,730 shares valued at $43.49 million.

Organon & Co. Stock Down 1.8%

Shares of NYSE:OGN are trading near $13.44. Organon & Co. has a market capitalization of roughly $3.53 billion and a price-to-earnings ratio of 14.45. The stock's 52-week range spans from a low of $5.69 to a high of $13.49. It has a 50-day moving average of $11.88 and a 200-day moving average of $9.04. The company maintains a current ratio of 1.97 and a quick ratio of 1.0, with a high debt-to-equity ratio of 948.95.

Recent Earnings

Organon & Co. reported revenues of approximately $6.16 billion, although it experienced a slight decline in revenue growth of 3.5%. The company's net margin stands at 3.99%, with a return on equity of 34.05%. Earnings per share were $0.93. The next earnings report is expected on August 4, 2026.

Dividend

Organon & Co. offers an annual dividend rate of $0.08, yielding 0.6%. The dividend payout ratio is a modest 8.6%, allowing the company to reinvest in growth.

Analysts Set New Price Targets

Analyst opinions on Organon & Co. are varied. On April 29, 2026, BNP Paribas downgraded the stock to a 'hold' with a $14 price target. Piper Sandler, on April 28, upgraded it to a 'hold' with the same target. Barclays maintained a 'sell' rating with an $8 target on February 24. The consensus mean price target is $11.25, based on four analyst opinions.

About Organon & Co.

Organon & Co., headquartered in Jersey City, New Jersey, focuses on women's health solutions, offering a range of prescription therapies and medical devices. The company operates across multiple regions, including the U.S., Europe, and Asia. Its portfolio includes contraception and fertility products, immunology and oncology biosimilars, and medications for cholesterol, hypertension, and respiratory conditions. Organon also provides dermatology and bone health products, serving a diverse clientele from wholesalers to hospitals.

Bottom Line

Helene Gayle's recent share purchase reflects a positive outlook on Organon & Co.'s future. As a significant player in the healthcare sector, Organon continues to attract institutional interest, evidenced by recent large-scale investments. Analyst views are mixed, but the company's strong fundamentals and global reach remain key points of interest for investors.